Analyst Price Target is $19.80
▲ +169.75% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Curis in the last 3 months. The average price target is $19.80, with a high forecast of $24.00 and a low forecast of $15.00. The average price target represents a 169.75% upside from the last price of $7.34.
Current Consensus is
The current consensus among 5 investment analysts is to buy stock in Curis.
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.